

July, 2009

Columbus CCOP  
1335 Dublin Road, Suite  
124-A  
Columbus, OH 43215

Phone: 614-488-2118  
Fax: 614-488-2647  
[www.columbusccop.org](http://www.columbusccop.org)

# CCOP NEWS



A Community of Caring in Cancer Research

## Columbus Community Clinical Oncology Program

### 2009 ASCO REVIEW

The Columbus CCOP's 2009 ASCO Review, held on June 18th, was well attended with 248 physicians, nurses and other healthcare professionals attending. This year's event once again featured nationally recognized experts who discussed the most current developments in cancer care presented at the ASCO '09 Annual Meeting.

This annual program was made possible through the generous support of the following companies and organizations: Abraxis Oncology, Amgen, Biogen Idec, Bristol-Myers Squibb, Celgene Corporation, Cephalon, Genentech, Genomic Healthcare, GlaxoSmithKline, Lilly, Merck & Co., Millennium, Myriad Genetics, Novartis, Ortho Biotech, OSI Pharmaceuticals, Pfizer, Roche Pharmaceuticals, Schering Plough, Susan G. Komen, and sanofi aventis



Dr. Kuebler  
Moderator



Dr. Markman  
Gynecologic  
Malignancies



Dr. Socinski  
Lung Cancer



Dr. Gilbert  
Brain Cancer



Dr. Raghavan  
GU Cancers



Dr. Loprinzi  
Cancer Control



Dr. Fisher  
Lymphoma



Break time!



Dr. Goldberg  
GI Cancers



Dr. Isaacs  
Breast Cancer



2009 ASCO Review  
audience

**OUR MISSION:** The Columbus Community Clinical Oncology Program (Columbus CCOP) strives to deliver state-of-the-art cancer care to patients in their communities through clinical trials. This allows individuals to remain in their own neighborhoods while receiving the latest and best in cancer screenings, diagnostic care and treatment plans.

Please send newsletter comments to [steveo@columbusccop.org](mailto:steveo@columbusccop.org)



## DR. KUEBLER'S CCOP UPDATES

KUEBLER'S

O  
R  
N  
E  
R



I hope your summer has been fun and productive at the same time. The latest news at the CCOP central office is that the competitive renewal grant has been completed and submitted to the NCI. Your CCOP central staff can now begin to enjoy some of those summer hours.

I would like to thank all of you who were “bugged” by us to supply data, write support letters and share registry information. All of this information must be included in the grant and your timely replies allowed us to meet our deadlines. By the way, the grant ran to 358 pages in length. I am glad I cannot be on the study section which reviews all CCOP grant requests this year. Someone will have to read all this information and up to 17—20 grants are submitted each year.

I also want to thank all those at the CCOP central office who worked diligently and beyond scheduled hours to get this grant out on time. Special kudos to Bernita White in this regard!

Now the wait begins. The study section meets in November (don't ask why the due date is in July!) We will hear something in early 2010. We are one of the original CCOP programs with continued funding since 1983 and we compete with all the other top CCOPs who also have had uninterrupted funding. We have succeeded in achieving most of our goals, we continue to have a strong presence in the research community and I am quite satisfied we have communicated this in our grant. Thus, I have every confidence our program will continue to be funded. That success will be your achievement. Thanks to all of you!



Columbus CCOP Principal Investigator




Please welcome Dr Hong Zhang to the Columbus CCOP. Dr. Zhang is a radiation oncologist practicing with Newark Radiation Oncology,

## NCI TRIAL NEWS

The following trial is now open for accrual:

**NCCTG N08C3: (Version date 04/17/2009)** Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Prevention of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy.

**Protocol and consent forms can be found at [www.columbusccop.org](http://www.columbusccop.org)**




## MARK YOUR CALENDAR

**Rescheduled:** Dr. Zale Bernstein's presentation titled **A Clinical Perspective on the Treatment of Non-Hodgkin's Lymphoma** has been postponed. The new date will be announced soon.



**September 16, 2009: Myelodysplastic Syndromes.** This CME evening program will be presented by Dr. William Blum of The Ohio State University. The location is McCormick and Schmick's at Easton Towne Center. Registration information will be available soon.



## DID YOU KNOW?

The American Cancer Society (ACS) provides free Online Continuing Medical Education (CME) for physicians and other health care professionals. Although developed to help professionals maintain and improve their knowledge of cancer prevention, detection, diagnosis, treatment, and palliative care, ACS CME material may be viewed by any Web user.



ACS CME consists of journal based activities and quizzes from *CA: A Cancer Journal for Clinicians*, as well as multimedia activities based on ACS guidelines for prevention and early detection of cancer. Such features as online scoring of quizzes, automatic tracking of CME credit hours earned, and printable certificates make the ACS CME experience convenient and efficient.

ACS CME courses can be found at:

[http://www.cancer.org/docroot/PRO/content/PRO\\_2\\_Continuing\\_Medical\\_Education.asp](http://www.cancer.org/docroot/PRO/content/PRO_2_Continuing_Medical_Education.asp)

2009 courses include:

- Screening for Prostate Cancer
- Making Difficult Discussions Easier: Using Prognosis to Facilitate Transitions to Hospice
- Advances in Understanding and Management of Myeloproliferative Neoplasms
- Local Surgical, Ablative, and Radiation Treatment of Metastases
- Novel Agents on the Horizon for Cancer Therapy
- Thyroid Aspiration Cytology: Current Status
- Cutaneous Manifestations of Internal Malignancy
- Cancer Screening in the United States, 2009: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening
- Patient Adherence and Persistence with Oral Anticancer Treatment
- Pharmacogenetics and Pharmacogenomics of Anticancer Agents
- Lymphedema: A Primer on the Identification and Management of a Chronic Condition in Oncologic Treatment

A handwritten signature in black ink, appearing to read 'Roeluy', is located in the bottom right corner of the 'DID YOU KNOW?' section.

Columbus CCOP  
Executive Director





## COMMUNITY CLINICAL ONCOLOGY PROGRAM HISTORY

The Community Clinical Oncology Program plays a key role in cancer research by providing the latest in cancer care to individuals in their communities through clinical trials.

The national Community Clinical Oncology Program evolved in the 1980's when the National Cancer Institute (NCI) began looking for ways to provide the best possible quality of care to cancer patients, regardless of their location. It was found that about 85% of cancer patients were being treated in their communities, rather than larger cancer treatment centers. Therefore, it was felt that community participation in clinical trials would be beneficial for both community physicians and their patients.

In 1983 the first CCOPs began through a grant program funded by The National Cancer Institute. This very important program partnered community cancer specialists and primary care physicians to participate in Cooperative Group (research bases) clinical trials, bringing cutting edge cancer care to patients in their communities.

In 1986 the CCOP program was expanded to include cancer prevention and control trials. This allowed CCOPs to provide a full range of cancer care within the community. Today, one-third of all patients accrued to NCI sponsored treatment, prevention and control clinical trials are accrued through CCOPs. There are currently 50 CCOPs in 35 states across the country, the District of Columbia, and Puerto Rico. Over 4,000 physicians participate in NCI clinical trials through the CCOP program. Over 172,000 patients have been enrolled by CCOPs in treatment and prevention trials.



## Our Mission...

is to deliver state-of-the-art cancer care to patients in their communities through clinical trials. This allows individuals to remain in their own neighborhoods while receiving the latest and best in cancer screenings, diagnostic care and treatment plans.